Novartis AG Common Stock (NVS)

SG&A Expenses

$3.24B

Quarterly · Period ending: · USD

NVS logo

NVS SG&A Expenses

Latest reported$3.24B
NVS Quarterly SG&A Expenses ($0.00 → $3.24B)
High-resolution chart · PNG

NVS sg&a expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novartis AG Common Stock SG&A Expenses — Quarterly (USD)
Period endingSG&A Expenses (USD)
3,243,221,000
3,140,000,000
3,435,739,000
3,308,000,000
3,442,000,000
3,058,000,000
3,501,000,000
3,134,000,000
3,091,000,000
2,840,000,000
3,444,000,000
3,091,000,000
3,091,000,000
2,891,000,000
3,747,000,000
2,936,000,000
3,581,000,000
3,512,000,000
3,985,000,000
3,618,000,000
3,754,000,000
3,529,000,000
3,924,000,000
3,419,000,000
3,368,000,000
3,486,000,000
3,905,000,000
3,549,000,000
3,585,000,000
3,330,000,000
4,404,000,000
3,261,000,000
3,495,000,000
3,284,000,000
4,041,000,000
3,678,000,000
3,806,000,000
3,472,000,000
3,838,000,000
3,400,000,000
3,649,000,000
3,305,000,000
3,885,000,000
3,463,000,000
3,617,000,000
3,282,000,000
3,965,000,000
3,565,000,000
3,826,000,000
3,637,000,000
4,776,000,000
3,674,000,000
3,784,000,000
4,218,000,000
4,640,000,000
4,086,000,000
4,350,000,000
4,214,000,000
4,803,000,000
4,386,000,000
4,642,000,000
4,218,000,000
4,784,000,000
3,741,000,000
3,688,000,000
3,584,000,000
4,168,000,000
3,405,000,000
3,532,000,000
3,226,000,000
3,683,000,000
3,415,000,000
3,665,000,000
3,334,000,000
3,679,000,000
3,181,000,000
3,329,000,000
3,070,000,000
3,343,000,000
2,924,000,000
2,965,000,000
2,698,000,000
3,137,000,000
2,821,000,000
2,866,000,000
2,720,000,000
2,952,000,000
2,470,000,000
2,576,000,000
2,662,000,000
2,424,000,000
2,363,000,000
2,374,000,000
2,164,000,000
3,063,000,000
1,930,000,000
2,143,000,000
0
0
0
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.